PUMA BIOTECHNOLOGY, INC.: accounts_receivable
| Value | {"amount": 47837000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2023-12-31) |
| Status | current |
| Entity | PUMA BIOTECHNOLOGY, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T13:37:34.551981+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/0624ceab-bd6d-4f8c-9499-1eeacfe62129
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001437749-24-006121Retrieved: 2026-08-19T13:37:34.551981+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001401667/accounts-receivable/2023-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/0624ceab-bd6d-4f8c-9499-1eeacfe62129
History
- no predecessors — first report